Related Experiment Videos
TIRC7 pathway as a target for preventing allograft rejection
Akihiko Tamura1, Edgar L Milford, Nalân Utku
1Institute of Medical Immunology, Campus Mitte, Charite, Humboldt-University of Berlin, Schumannstrasse 20/21, Berlin, Germany. nalan.utku@charite.de
Drug News & Perspectives
|May 11, 2005
Summary
Targeting the novel T-cell immune response cDNA 7 (TIRC7) molecule with antibodies shows promise for preventing organ transplant rejection. Monitoring TIRC7 expression may also aid in diagnosing acute rejection, offering a theranostic approach.
Area of Science:
- Immunology
- Transplantation Biology
- Molecular Medicine
Background:
- Leukocyte surface molecules are crucial for immune activation and are targets for therapeutic antibodies.
- Antibodies targeting leukocyte molecules can induce transplant tolerance in animal models.
- A novel, conserved membrane protein, T-cell immune response cDNA 7 (TIRC7), regulates lymphocyte activation.
Purpose of the Study:
- To investigate the role of TIRC7 in immune responses and its potential as a therapeutic target for preventing allograft rejection.
- To explore the diagnostic utility of TIRC7 expression in acute transplant rejection.
Main Methods:
- Utilized antibodies against extracellular domains of TIRC7 in rat and mouse transplantation models.
- Performed functional cellular assays with TIRC7-deficient mice splenocytes.
- Analyzed TIRC7 expression in acutely rejected human kidney allografts.
Main Results:
- Antibodies against TIRC7 prolonged allograft survival in animal models, partly via CTLA4 induction.
- TIRC7 deficiency impacted both T-cell and B-cell responses.
- Combined subtherapeutic doses of FK506 and anti-TIRC7 antibody showed synergistic effects on graft survival.
- High TIRC7 expression was observed in acutely rejected human kidney allografts.
Conclusions:
- Targeting TIRC7 with monoclonal antibodies is a potential therapeutic strategy for preventing allograft rejection and treating immune-related diseases.
- Monitoring TIRC7 expression could serve as an early diagnostic tool for acute rejection.
- TIRC7 represents a theranostic target with dual diagnostic and therapeutic applications in transplantation and immune diseases.